Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H18ClN5 |
Molecular Weight | 351.833 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N12
InChI
InChIKey=GJSLOMWRLALDCT-UHFFFAOYSA-N
InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3
Molecular Formula | C19H18ClN5 |
Molecular Weight | 351.833 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Adinazolam, a benzodiazepine agonist, is an effective anxiolytic agent with antidepressant properties. It was shown, that adinazolam by itself had relatively weak benzodiazepine agonist activity, and much of the pharmacological activity belonged to its active metabolite N-desmethyladinazolam (NDMAD). Adinazolam has never been FDA approved, but it is sold as a research chemical.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2109243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6148400 |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. | 1983 Nov |
|
Determination of biological activity of adinazolam and its metabolites. | 1984 Aug |
|
Triazolobenzodiazepines antagonize the effects of anxiogenic drugs mediated at three different central nervous system sites. | 1985 Oct 24 |
|
The effects of chronic antidepressant treatment in an animal model of anxiety. | 1988 |
|
Inhibition of the binding and the behavioral effects of thyrotropin-releasing hormone (TRH) by the triazolobenzodiazepines. | 1988 May |
|
Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. | 1989 Feb |
|
The early acquisition of two-way (shuttle-box) avoidance as an anxiety-mediated behavior: psychopharmacological validation. | 1991 Jan |
|
Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment. | 1991 Nov |
|
Platelet alpha-2 adrenoreceptor activity pre-treatment and post-treatment in major depressive disorder with melancholia. | 1991 Oct |
|
Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. | 1992 Aug |
|
Benzodiazepine suppression of corticotropin-releasing factor (CRF)-induced beta-endorphin release from rat neurointermediate pituitary. | 1992 Sep-Oct |
|
Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. | 1993 |
|
Evidence that decreased function of lymphocyte beta adrenoreceptors reflects regulatory and adaptive processes in panic disorder with agoraphobia. | 1993 Aug |
|
Flumazenil prevents the anxiolytic effects of diazepam, alprazolam and adinazolam on the early acquisition of two-way active avoidance. | 1993 Jul-Aug |
|
Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. | 1998 Mar |
|
A follow-up study of DSM-III-R generalized anxiety disorder with syndromal and subsyndromal major depression. | 2003 Feb |
|
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. | 2003 Feb 28 |
|
Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. | 2005 May |
|
Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. | 2007 Jul |
|
The effect of sympathetic antagonists on the antidepressant action of alprazolam. | 2008 Jun 1 |
|
The enduring effects of an adolescent social stressor on synaptic density, part II: Poststress reversal of synaptic loss in the cortex by adinazolam and MK-801. | 2008 Mar |
|
Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. | 2009 Jun |
|
Recent trends in the impurity profile of pharmaceuticals. | 2010 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3298327
from 90 to 40 mg/day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:45:49 GMT 2023
by
admin
on
Sat Dec 16 17:45:49 GMT 2023
|
Record UNII |
KN08449444
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05BA07
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
||
|
WHO-ATC |
N05BA07
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Adinazolam
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
KN08449444
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
37632
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
DTXSID40190611
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
ADINAZOLAM
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
100000087684
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
93
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
C76531
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL328250
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
m1418
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
4996
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
SUB05271MIG
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
C039668
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
251412
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
DB00546
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY | |||
|
37115-32-5
Created by
admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |